Improvement of atazanavir-induced hyperbilirubinaemia following TDM-guided atazanavir dose reduction

Purpose of the study To confirm in our cohort of patients the correlation between hyperbilirubinaemia (defined as unconjugated bilirubin >2 mg/dL and/or total bilirubin >2.5 mg/dL) and elevated atazanavir (ATV) trough levels (i.e. >750 ng/ mL), and to assess the efficacy of a therapeutic drug monitoring (TDM)-guided ATV dose reduction in order to improve the clinical impact of this adverse event.